Cargando…

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis

BACKGROUND: Hemophilia A (HA) is an inherited X-linked bleeding disease with costly treatment, especially for high titer inhibitory patients. Emicizumab, a new humanized bispecific antibody, has been approved for use to prevent or reduce the frequency of bleeding episodes in HA patients with inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saiyarsarai, Parisa, Robabpour Derakhshan, Atefeh, Khedmati, Jamaleddin, Eshghi, Peyman, Seyedifar, Meysam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	4200
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500655/ https://www.ncbi.nlm.nih.gov/pubmed/34622828 http://dx.doi.org/10.1097/MD.0000000000027303

Ejemplares similares

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018)

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England
por: Spivey, MH, et al.
Publicado: (2010)

Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report
por: Ma, Hongbing, et al.
Publicado: (2021)

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021)

Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood
por: Haidl, Harald, et al.
Publicado: (2019)

Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran
por: Saiyarsarai, Parisa, et al.
Publicado: (2020)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury
por: Smith, Jason E, et al.
Publicado: (2019)

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience
por: Shah, Nurfatin Mohd, et al.
Publicado: (2018)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit
por: Bonadona, A, et al.
Publicado: (2002)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use
por: Bomken, Charlotte, et al.
Publicado: (2009)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
por: Kim, Bobby, et al.
Publicado: (2014)

Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa): A Case Report
por: Alabed, Iehab B.
Publicado: (2014)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding
por: Milanov, S, et al.
Publicado: (2003)

Thromboelastometry as an Ancillary Tool for Evaluation of Coagulation Status after rFVIIa Therapy in a Pregnant Woman with Severe Hypoproconvertinemia—A Case Series and Review of the Literature
por: Krzyżanowski, Arkadiusz, et al.
Publicado: (2022)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Management of children with hemophilia A on emicizumab who need surgery
por: Belletrutti, Mark, et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

Comparing Characteristics of Adverse Drug Events Between Older and Younger Adults Presenting to a Taiwan Emergency Department
por: Chen, Yen-Chia, et al.
Publicado: (2015)

Adjuvant therapy use among Appalachian breast cancer survivors
por: Tan, Xi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5srak3ahsjeugmjjqh9560fh5i